BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 34847775)

  • 1. MYC regulates metabolism through vesicular transfer of glycolytic kinases.
    Tsakaneli A; Carregari VC; Morini M; Eva A; Cangemi G; Chayka O; Makarov E; Bibbò S; Capone E; Sala G; De Laurenzi V; Poon E; Chesler L; Pieroni L; Larsen MR; Palmisano G; Sala A
    Open Biol; 2021 Dec; 11(12):210276. PubMed ID: 34847775
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MYCN controls an alternative RNA splicing program in high-risk metastatic neuroblastoma.
    Zhang S; Wei JS; Li SQ; Badgett TC; Song YK; Agarwal S; Coarfa C; Tolman C; Hurd L; Liao H; He J; Wen X; Liu Z; Thiele CJ; Westermann F; Asgharzadeh S; Seeger RC; Maris JM; Guidry Auvil JM; Smith MA; Kolaczyk ED; Shohet J; Khan J
    Cancer Lett; 2016 Feb; 371(2):214-24. PubMed ID: 26683771
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination therapy with the CDK7 inhibitor and the tyrosine kinase inhibitor exerts synergistic anticancer effects against MYCN-amplified neuroblastoma.
    Tee AE; Ciampa OC; Wong M; Fletcher JI; Kamili A; Chen J; Ho N; Sun Y; Carter DR; Cheung BB; Marshall GM; Liu PY; Liu T
    Int J Cancer; 2020 Oct; 147(7):1928-1938. PubMed ID: 32086952
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification and pharmacological inactivation of the MYCN gene network as a therapeutic strategy for neuroblastic tumor cells.
    Chayka O; D'Acunto CW; Middleton O; Arab M; Sala A
    J Biol Chem; 2015 Jan; 290(4):2198-212. PubMed ID: 25477524
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantitative Proteomics of Th-MYCN Transgenic Mice Reveals Aurora Kinase Inhibitor Altered Metabolic Pathways and Enhanced ACADM To Suppress Neuroblastoma Progression.
    Hsieh CH; Cheung CHY; Liu YL; Hou CL; Hsu CL; Huang CT; Yang TS; Chen SF; Chen CN; Hsu WM; Huang HC; Juan HF
    J Proteome Res; 2019 Nov; 18(11):3850-3866. PubMed ID: 31560547
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lack of correlation between MYCN expression and the Warburg effect in neuroblastoma cell lines.
    Smith DJ; Cossins LR; Hatzinisiriou I; Haber M; Nagley P
    BMC Cancer; 2008 Sep; 8():259. PubMed ID: 18789162
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Novel MYCN-Specific Antigene Oligonucleotide Deregulates Mitochondria and Inhibits Tumor Growth in MYCN-Amplified Neuroblastoma.
    Montemurro L; Raieli S; Angelucci S; Bartolucci D; Amadesi C; Lampis S; Scardovi AL; Venturelli L; Nieddu G; Cerisoli L; Fischer M; Teti G; Falconi M; Pession A; Hrelia P; Tonelli R
    Cancer Res; 2019 Dec; 79(24):6166-6177. PubMed ID: 31615807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MYCN promotes neuroblastoma malignancy by establishing a regulatory circuit with transcription factor AP4.
    Xue C; Yu DM; Gherardi S; Koach J; Milazzo G; Gamble L; Liu B; Valli E; Russell AJ; London WB; Liu T; Cheung BB; Marshall GM; Perini G; Haber M; Norris MD
    Oncotarget; 2016 Aug; 7(34):54937-54951. PubMed ID: 27448979
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumorigenic proteins upregulated in the MYCN-amplified IMR-32 human neuroblastoma cells promote proliferation and migration.
    Zaatiti H; Abdallah J; Nasr Z; Khazen G; Sandler A; Abou-Antoun TJ
    Int J Oncol; 2018 Mar; 52(3):787-803. PubMed ID: 29328367
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interplay between MycN and c-Myc regulates radioresistance and cancer stem cell phenotype in neuroblastoma upon glutamine deprivation.
    Le Grand M; Mukha A; Püschel J; Valli E; Kamili A; Vittorio O; Dubrovska A; Kavallaris M
    Theranostics; 2020; 10(14):6411-6429. PubMed ID: 32483461
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A combined gene expression and functional study reveals the crosstalk between N-Myc and differentiation-inducing microRNAs in neuroblastoma cells.
    Zhao Z; Ma X; Shelton SD; Sung DC; Li M; Hernandez D; Zhang M; Losiewicz MD; Chen Y; Pertsemlidis A; Yu X; Liu Y; Du L
    Oncotarget; 2016 Nov; 7(48):79372-79387. PubMed ID: 27764804
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MYCN-induced E2F5 promotes neuroblastoma cell proliferation through regulating cell cycle progression.
    Liu Y; Liu D; Wan W
    Biochem Biophys Res Commun; 2019 Mar; 511(1):35-40. PubMed ID: 30765227
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proliferation and Survival of Embryonic Sympathetic Neuroblasts by MYCN and Activated ALK Signaling.
    Kramer M; Ribeiro D; Arsenian-Henriksson M; Deller T; Rohrer H
    J Neurosci; 2016 Oct; 36(40):10425-10439. PubMed ID: 27707976
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Zimmerman MW; Liu Y; He S; Durbin AD; Abraham BJ; Easton J; Shao Y; Xu B; Zhu S; Zhang X; Li Z; Weichert-Leahey N; Young RA; Zhang J; Look AT
    Cancer Discov; 2018 Mar; 8(3):320-335. PubMed ID: 29284669
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The PLAGL2/MYCN/miR-506-3p interplay regulates neuroblastoma cell fate and associates with neuroblastoma progression.
    Zhao Z; Shelton SD; Oviedo A; Baker AL; Bryant CP; Omidvarnia S; Du L
    J Exp Clin Cancer Res; 2020 Feb; 39(1):41. PubMed ID: 32087738
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NLRR1 enhances EGF-mediated MYCN induction in neuroblastoma and accelerates tumor growth in vivo.
    Hossain S; Takatori A; Nakamura Y; Suenaga Y; Kamijo T; Nakagawara A
    Cancer Res; 2012 Sep; 72(17):4587-96. PubMed ID: 22815527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hsp90 inhibition increases p53 expression and destabilizes MYCN and MYC in neuroblastoma.
    Regan PL; Jacobs J; Wang G; Torres J; Edo R; Friedmann J; Tang XX
    Int J Oncol; 2011 Jan; 38(1):105-12. PubMed ID: 21109931
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuroblastoma-derived v-myc avian myelocytomatosis viral related oncogene or
    Bhardwaj N; Das G; Srinivasan R
    J Clin Pathol; 2023 Aug; 76(8):518-523. PubMed ID: 37221048
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of mTOR-kinase destabilizes MYCN and is a potential therapy for MYCN-dependent tumors.
    Vaughan L; Clarke PA; Barker K; Chanthery Y; Gustafson CW; Tucker E; Renshaw J; Raynaud F; Li X; Burke R; Jamin Y; Robinson SP; Pearson A; Maira M; Weiss WA; Workman P; Chesler L
    Oncotarget; 2016 Sep; 7(36):57525-57544. PubMed ID: 27438153
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MYCN is amplified during S phase, and c‑myb is involved in controlling MYCN expression and amplification in MYCN‑amplified neuroblastoma cell lines.
    Aygun N; Altungoz O
    Mol Med Rep; 2019 Jan; 19(1):345-361. PubMed ID: 30483774
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.